Multiple market analysts recognise Euretos as leading AI company in drug development

At Euretos, we are driven by a deep desire to unravel the complexities of human disease biology. We are convinced that a better understanding of disease mechanisms on a molecular level reduces the risk and cost of therapy development. This leads to better and safer treatment options for more patients.

We generate data driven disease insights through a unique combination of AI driven, computational disease models, translational biology consultancy and direct access to the Euretos AI platform. This empowers our customers to draw their own conclusions and take a data driven approach to disease and drug research.

We are very happy to share that our contribution to disease and drug research has been recognized by three prominent industry analyst reports recently:

Vision Gain: Euretos has been recognized as one of the leading companies operating in the Pharmaceuticals Market in their recent Artificial Intelligence (AI) in Pharmaceutical Market Report 2021-20131.  In addition to revenue forecasting for 2031, this report provides you with recent results, growth rates, and market shares.

Research and Markets: Euretos has been featured as one of the major players in their recent Global Artificial Intelligence in Drug Discovery Market (2021 to 2028) - Share, Size, Trends and Industry Analysis Report. This report gives a detailed insight into current market dynamics and provides an analysis of future market growth.

Grand View Research: Euretos has been mentioned as one of the key players in their recent AI-based Clinical Trials Solution Provider Market Size, Share & Trends Analysis Report. Grand View Research has segmented the global AI-based clinical trials solution provider market based on clinical trial phase, therapeutic application, end-user, and region

We could not have achieved these recognitions without the combination of our client partnerships, our multi-disciplinary data & translational science teams and the Euretos AI platform. We are very happy with our progress and excited about the future innovations we plan to deliver. 

If you would like to know more about how we enable a data-driven approach to disease and drug research, don't hesitate to get in touch with us, and we will be happy to tell you more about it!